Oramed Pharmaceuticals (ORMP)
(Delayed Data from NSDQ)
$2.42 USD
-0.09 (-3.59%)
Updated Sep 18, 2024 04:00 PM ET
After-Market: $2.42 0.00 (0.00%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
0 items in cart
Oramed Pharmaceuticals Inc. [ORMP]
Reports for Purchase
Showing records 21 - 40 ( 81 total )
Company: Oramed Pharmaceuticals Inc.
Industry: Medical - Products
Leptin Candidate Initial Clinical Data Reported; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Oramed Pharmaceuticals Inc.
Industry: Medical - Products
ORMD-0801 Global Phase 3 Program Patient Screening Begins; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Oramed Pharmaceuticals Inc.
Industry: Medical - Products
Phase 3 Program Poised to Advance; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Oramed Pharmaceuticals Inc.
Industry: Medical - Products
Positive End-of-Phase 2 Meeting With FDA; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Oramed Pharmaceuticals Inc.
Industry: Medical - Products
Company: Oramed Pharmaceuticals Inc.
Industry: Medical - Products
Initial Fatty Liver Trial Data; Reiterate Buy; Lowering PT to $16
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Oramed Pharmaceuticals Inc.
Industry: Medical - Products
Provider: Zacks Investment Research
Analyst: Research Department
Company: Oramed Pharmaceuticals Inc.
Industry: Medical - Products
Provider: Zacks Investment Research
Analyst: Research Department
Company: Oramed Pharmaceuticals Inc.
Industry: Medical - Products
Provider: Zacks Investment Research
Analyst: Research Department
Company: Oramed Pharmaceuticals Inc.
Industry: Medical - Products
Last Patient Dosed in ORMD-0801 Phase 2b Trial; Top-Line Readout Next Month; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Oramed Pharmaceuticals Inc.
Industry: Medical - Products
F3Q19 Financial Results Reported; Clinical Programs Advancing; Modulating Target to $20
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Oramed Pharmaceuticals Inc.
Industry: Medical - Products
Company: Oramed Pharmaceuticals Inc.
Industry: Medical - Products
Multiple Clinical Data Catalysts Near-Term; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Oramed Pharmaceuticals Inc.
Industry: Medical - Products
Phase 2b Trial Enrollment Completed; Top-Line Data in 4Q19; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Oramed Pharmaceuticals Inc.
Industry: Medical - Products
Phase 2b Trial Enrollment Completed; Top-Line Data in 4Q19; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Oramed Pharmaceuticals Inc.
Industry: Medical - Products
Company: Oramed Pharmaceuticals Inc.
Industry: Medical - Products
F1Q19 Financial Results Reported; Oral Exenatide Patent Allowed; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Oramed Pharmaceuticals Inc.
Industry: Medical - Products
Chinese Partner Receives ORMD-0801 Clinical Testing Authorization; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Oramed Pharmaceuticals Inc.
Industry: Medical - Products
Company: Oramed Pharmaceuticals Inc.
Industry: Medical - Products
ORMD-0901 Enters Phase 1 Testing; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R